Aim to Reduce Movements in Tardive Dyskinesia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Tardive Dyskinesia
Interventions
DRUG

SD-809

SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.

DRUG

Placebo

Placebo tablets taken twice daily for 12 weeks.

Trial Locations (41)

Unknown

Tuscaloosa

Anaheim

Glendale

Oceanside

Orange

San Bernardino

San Diego

Denver

New Haven

Stamford

Washington D.C.

Boca Raton

Gainesville

Lake City

Miami

Orlando

Port Charlotte

Chicago

Baltimore

Minneapolis

Kansas City

St Louis

Albuquerque

Asheville

Durham

Raleigh

Cleveland

Philadelphia

Charleston

Memphis

Fort Worth

Salt Lake City

Prague

Gdansk

Katowice

Krakow

Lodz

Lublin

Torun

Domaša

Rožňava

Sponsors
All Listed Sponsors
lead

Auspex Pharmaceuticals, Inc.

INDUSTRY

NCT02195700 - Aim to Reduce Movements in Tardive Dyskinesia | Biotech Hunter | Biotech Hunter